HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epigenetic reprogramming converts human Wharton's jelly mesenchymal stem cells into functional cardiomyocytes by differential regulation of Wnt mediators.

AbstractBACKGROUND:
Lineage commitment of mesenchymal stem cells (MSCs) to cardiac differentiation is controlled by transcription factors that are regulated by epigenetic events, mainly histone deacetylation and promoter DNA methylation. Here, we studied the differentiation of human Wharton's jelly MSCs (WJMSCs) into the cardiomyocyte lineage via epigenetic manipulations.
METHODS:
We introduced these changes using inhibitors of DNA methyl transferase and histone deacetylase, DC301, DC302, and DC303, in various combinations. We characterized for cardiogenic differentiation by assessing the expression of cardiac-specific markers by immunolocalization, quantitative RT-PCR, and flow cytometry. Cardiac functional studies were performed by FURA2AM staining and Greiss assay. The role of Wnt signaling during cardiac differentiation was analyzed by quantitative RT-PCR. In-vivo studies were performed in a doxorubicin-induced cardiotoxic mouse model by injecting cardiac progenitor cells. Promoter methylation status of the cardiac transcription factor Nkx2.5 and the Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), after cardiac differentiation was studied by bisulfite sequencing.
RESULTS:
By induction with DC301 and DC302, WJMSCs differentiated into cardiomyocyte-like structures with an upregulation of Wnt antagonists, sFRP3 and sFRP4, and Dickkopf (Dkk)1 and Dkk3. The cardiac function enhancer, vinculin, and DDX20, a DEAD-box RNA helicase, were also upregulated in differentiated cardiomyocytes. Additionally, bisulfite sequencing revealed, for the first time in cardiogenesis, that sFRP4 is activated by promoter CpG island demethylation. In vivo, these MSC-derived cardiac progenitors could not only successfully engraft to the site of cardiac injury in mice with doxorubicin-induced cardiac injury, but also form functional cardiomyocytes and restore cardiac function.
CONCLUSION:
The present study unveils a link between Wnt inhibition and epigenetic modification to initiate cardiac differentiation, which could enhance the efficacy of stem cell therapy for ischemic heart disorders.
AuthorsG Bhuvanalakshmi, Frank Arfuso, Alan Prem Kumar, Arun Dharmarajan, Sudha Warrier
JournalStem cell research & therapy (Stem Cell Res Ther) Vol. 8 Issue 1 Pg. 185 (08 14 2017) ISSN: 1757-6512 [Electronic] England
PMID28807014 (Publication Type: Journal Article)
Chemical References
  • Adaptor Proteins, Signal Transducing
  • Chemokines
  • DKK1 protein, human
  • DKK3 protein, human
  • Homeobox Protein Nkx-2.5
  • Intercellular Signaling Peptides and Proteins
  • NKX2-5 protein, human
  • Proto-Oncogene Proteins
  • SFRP4 protein, human
  • Wnt Proteins
  • Nitric Oxide
  • Calcium
Topics
  • Adaptor Proteins, Signal Transducing
  • Animals
  • Base Sequence
  • Calcium (metabolism)
  • Cell Differentiation (genetics)
  • Cell Separation
  • Cellular Reprogramming (genetics)
  • Chemokines
  • CpG Islands (genetics)
  • DNA Demethylation
  • Epigenesis, Genetic
  • Fibrosis
  • Homeobox Protein Nkx-2.5 (metabolism)
  • Humans
  • Intercellular Signaling Peptides and Proteins (genetics, metabolism)
  • Male
  • Mesenchymal Stem Cells (cytology)
  • Mice, Inbred C57BL
  • Myocardium (pathology)
  • Myocytes, Cardiac (cytology, metabolism, transplantation)
  • Nitric Oxide (metabolism)
  • Organogenesis (genetics)
  • Promoter Regions, Genetic (genetics)
  • Proto-Oncogene Proteins (genetics, metabolism)
  • Up-Regulation (genetics)
  • Wharton Jelly (cytology)
  • Wnt Proteins (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: